title: Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.
abstract: Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and the identification of markers predictive of outcome is mandatory. In this review, taking into account the currently available literature, we report the impact that host genetic variables can have on EC neoadjuvant therapy. We mainly focused on the gene variants involved in the pharmacokinetics and pharmacodynamics of the common chemotherapeutic drugs used to treat EC patients, commented on the weakness of the present knowledge, and discussed the future strategies to achieve a more personalized and effective EC treatment.
authors.affiliation: Immunology & Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
authors.forename: Enrica
authors.initials: E
authors.lastname: Rumiato
authors.affiliation: Immunology & Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Boldrin
authors.affiliation: Immunology & Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.|Department of Surgical Sciences, Oncology & Gastroenterology, University of Padova, Padova, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Amadori
authors.affiliation: Immunology & Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Saggioro
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D059248:Chemoradiotherapy; D004260:DNA Repair / Q000187:drug effects / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D020360:Neoadjuvant Therapy; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: esophageal cancer; neoadjuvant chemotherapy; pharmacogenetics; polymorphism; predictive marker; therapy outcome